CO-OPTIV-SECURIT
10.6.2019 15:07:06 CEST | Business Wire | Press release
Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has been recognized by Forrester Research as a Strong Performer in The Forrester WaveTM : Global Cybersecurity Consulting Providers, Q2 2019. The report identifies Optiv as having received the highest possible score for six criteria:
- Delivery and engagement innovation
- IP and asset-based consulting
- Technical consulting and assessment capabilities
- Cybersecurity focus
- Go-to-market strategy
- Partnership ecosystems
“Optiv’s approach to cybersecurity is aligned to new business models and centered on driving client-focused outcomes. It is designed to optimize and rationalize existing cybersecurity programs, build new integrated, end to end cybersecurity programs, and help clients transform how they are consuming and applying cybersecurity,” said Bryan Wiese, division vice president, global advisory services for Optiv.
“We believe that receiving this designation from Forrester as a Strong Performer affirms our approach to consulting for global enterprises,” continued Wiese. “Historically, the fear of external threats and vulnerabilities has often guided clients’ security initiatives. That fear has sometimes led to tactical investment, too much of a focus on technology, and siloed problem solving. At Optiv we work with clients to manage their security programs from the ‘inside-out,’ starting with risk mitigation and building from there with customized strategy, focused process definition, technology rationalization and operations optimization, ongoing measurement and communication. Our approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change by providing new consumption and outcome-based consulting services and cybersecurity solutions. Our goal is help clients strike the right balance between risk mitigation, business alignment, and cost.”
Optiv’s full suite of advisory services can be consumed alone or combined with Optiv’s integration or managed services, or Cyber-as-a-Service (CaaSTM ) platform to harden security fundamentals across six main domains:
- Risk Management and Transformation – Optiv enables clients to address risk and regulatory changes with an inside-out strategy that begins with business needs and applies strategy, technology and processes to effectively manage risk and enable cyber resilience.
- Cyber Operations – Optiv helps clients strike the right balance of people, process, technologies and delivery methods in order to elevate threat preparedness while aligning business goals and operational resilience and producing measurable outcomes at reduced operational costs.
- Cyber Digital Transformation – Optiv aligns client business needs with a security-by-design approach that employs big data analytics, IoT, cloud, orchestration and automation and additional technology innovations to connect agile processes and controls.
- Identity and Data Management – Optiv helps clients tackle identity and data sprawl and exposure with comprehensive, strategic identity and data management solutions. Enabling organizations to quickly and securely provide access to the right company assets on- and off-premise ensures trust and compliance in the business while also strengthening security by classifying, governing and protecting sensitive data.
- Threat Management – Proactively solving threat management requires a comprehensive program that includes tracking technological and regulatory changes, driving security into network design and software development lifecycles, continual threat modeling, testing and remediation, an understanding of the attack surface, and readiness exercises to practice muscle memory and robust response should an incident occur.
Please visit Optiv’s website to learn more about Optiv’s cybersecurity consulting services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005093/en/
Contact:
Brett Ater (913) 304-7683 brett.ater@optiv.com or Jason Cook (816) 701-3374 jason.cook@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
